Recent studies highlight that over 95 percent of plasma cell neoplasms display loss of CD19, marking a significant immunophenotypic abnormality identified through flow cytometry. This method is essential for diagnosing and monitoring multiple myeloma, allowing for differentiation between normal and neoplastic plasma cells by analyzing immunoglobulin light chain restriction and distinct immunophenotypic patterns. Normal plasma cells express CD19, while neoplastic forms often do not. Standardized panels improve accuracy in measurable residual disease testing, influencing treatment outcomes.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
